Name | Methyl N-{4-[(1H-imidazol-5-ylmethyl)amino]-2-(1-naphthyl)benzoyl}-L-leucinate |
---|---|
Synonyms |
Methyl N-{4-[(1H-imidazol-5-ylmethyl)amino]-2-(1-naphthyl)benzoyl}-L-leucinate
methyl N-{4-[(1H-imidazol-4-ylmethyl)amino]-2-(naphthalen-1-yl)benzoyl}-L-leucinate L-Leucine, N-[4-[(1H-imidazol-5-ylmethyl)amino]-2-(1-naphthalenyl)benzoyl]-, methyl ester |
Description | GGTI-2147 is a potent GGTase I inhibitor. GGTI-2147 blocks geranyl-geranylation of Rap1A and reduces the activity of Rac1 (one of substrates for GGTI) and ameliorates the OGD/R-induced neuronal apoptosis.GGTI-2147 can be used for neurodevelopmental disorders research, such as autism, depression, and schizophrenia[1]. |
---|---|
Related Catalog | |
References |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 710.6±60.0 °C at 760 mmHg |
Molecular Formula | C28H30N4O3 |
Molecular Weight | 470.563 |
Flash Point | 383.5±32.9 °C |
Exact Mass | 470.231781 |
LogP | 4.23 |
Vapour Pressure | 0.0±2.3 mmHg at 25°C |
Index of Refraction | 1.640 |